Background: The mainstay treatment of biliary tract cancer is complete tumor resection. Prior to surgery, risk stratification may help to predict and plan treatment approaches. In this study, we investigated the possibility of combining serum albumin concentrations and neutrophil-to-lymphocyte ratios (NLR) to create a score as ANS to predict the prognoses of biliary tract cancer before surgery. Methods: This study retrospectively collected serum albumin concentration, neutrophil, and lymphocyte data measured in biliary tract cancer patients slated to receive complete tumor resections within two weeks before surgery. From January 2013 to December 2019, 268 biliary tract cancer patients who had received tumor resections at our hospital were categorized into 3 ANS groups: ANS = 0 (high albumin and low NLR), ANS = 1 (low albumin or high NLR), and ANS = 2 (low albumin and high NLR). Results: Five-year survival rates were 70.1%, 47.6%, and 30.8% in the ANS = 0, 1, and 2 groups, respectively. The median overall survival time for the ANS = 0 group could not be determined by the end of the study, while those for ANS = 1 and ANS = 2 groups were 54.90 months and 16.62 months, respectively. The results of our multivariate analysis revealed that ANS could be used as an independent predictor of overall and recurrent-free survival. A high ANS was also correlated with other poor prognostic factors. Conclusions: The ANS devised for this study can be used to predict postoperative survival in patients with BTC and to guide treatment strategies.
背景：胆道癌的主要治疗手段是肿瘤完全切除。术前进行风险分层有助于预测和规划治疗方案。本研究探讨了结合血清白蛋白浓度与中性粒细胞-淋巴细胞比值（NLR）构建ANS评分系统，用于术前预测胆道癌患者预后的可行性。方法：本研究回顾性收集了计划接受肿瘤完全切除的胆道癌患者术前两周内测量的血清白蛋白浓度、中性粒细胞及淋巴细胞数据。2013年1月至2019年12月期间，将我院接受肿瘤切除的268例胆道癌患者分为3个ANS组：ANS=0组（高白蛋白且低NLR）、ANS=1组（低白蛋白或高NLR）及ANS=2组（低白蛋白且高NLR）。结果：ANS=0、1、2组的五年生存率分别为70.1%、47.6%和30.8%。研究结束时ANS=0组的中位总生存期尚未达到，而ANS=1组和ANS=2组分别为54.90个月和16.62个月。多变量分析结果显示，ANS可作为总生存期和无复发生存期的独立预测因子。较高的ANS评分也与其他不良预后因素相关。结论：本研究设计的ANS评分可用于预测胆道癌患者术后生存情况，并为治疗策略提供指导。
肿瘤(癌症)患者之家